Response Evaluation Criteria for Gastric Cancer Patients Following Preoperative Chemotherapy_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 李國立 , 劉坤 , 王緒林 , 范朝剛

Corresponding?author：

李國立, Email: drguoli@yahoo.com.cn

Keywords：

胃癌; 術前化療

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李國立,劉坤,王緒林,范朝剛. Response Evaluation Criteria for Gastric Cancer Patients Following Preoperative Chemotherapy. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(1): 12-15. doi: Copy

1.	Cunningham D,Allum,WH，Stenning,SP，et al.Perioperat-ive chemotherapy versus surgery alone for resectable gastroesoph-ageal cancer[J].N Engl J Med,2006,355(1)： 11-20.
2.	Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States, National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3)：205-216.
3.	World Health Organization.WHO handbook for reporting results of cancer treatment[M].Geneva, Switzerland：World Health Organization Offset Publication,1979：1-48.
4.	Therasse P,Eisenhauer EA,Verweij J.RECIST revisited：a review of validation studies on tumour assessment[J].Eur J Cancer，2006，42(8)：1031-1039.
5.	Lee SM,Kim SH,Lee JM,et al.Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoad-juvant chemotherapy in advanced gastric cancer[J].Abdom Imaging,2009,34(4)：430-440.
6.	Benjamin RS,Choi H,Macapinlac HA,et al.We should desist using recist,at least in GIST[J].J Clin Oncol,2007,25(13)：1760-1764.
7.	Ratain MJ,Eckhardt SG.PhaseⅡ studies of modern drugs directed against new targets：if you are fazed, too, then resist recist[J].J Clin Oncol， 2004， 22(22)：4442-4445.
8.	Choi H,Charnsangavej C,de Castro Faria S,et al.CT evaluationof the response of gastrointestinal stromal tumors after imatinib mesylate treatment： a quantitative analysis correlated with FDG PET findings[J].AJR Am J Roentgenol， 2004， 183(6)：1619-1628.
9.	Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy：importance of size and attenuation on contrast-enhancedct[J].AJR Am J Roentgenol， 2010， 194(1)：157-165.
10.	Chun YS,Vauthey JN, Boonsirikamchai P,et al.Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases[J].Jama， 2009， 302(21)：2338-2344.
11.	Stacchiotti S, Collini P, Messina A,et al.High-grade soft-tissue sarcomas：tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria[J]. Radiology， 2009， 251(2)：447-456.
12.	Miles KA. Tumour angiogenesis and its relation to contrast enha-ncement on computed tomography：a review[J]. Eur J Radiol，1999， 30(3)： 198-205.
13.	Miles KA, Charnsangavej C,Lee FT,et al.Application of CT in the investigation of angiogenesis in oncology[J].Acad Radiol， 2000， 7(10)：840-850.
14.	Beer AJ,Wieder HA,Lordick F,et al.Adenocarcinomas of es-ophagogastric junction： multi-detector row CT to evaluate early response to neoadjuvant chemotherapy[J].Radiology，2006，239(2)：472-480.
15.	Maitland ML. Volumes to learn：advancing therapeutics with innovative computed tomography image data analysis[J].Clin Cancer Res， 2010， 16(18)：4493-4495.
16.	Ott K, Herrmann K, Schuster T,et al.Molecular imaging of proliferation and glucose utilization： utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer[J].Ann Surg Oncol, 2011， 18(12)： 3316-3323.
17.	Rosenberg R, Herrmann K, Gertler R,et al.The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT[J].Int J Colorectal Dis， 2009， 24(2)：191-200.
18.	Herrmann K, Bundschuh RA, Rosenberg R,et al.Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI[J].Mol Imaging Biol, 2011， 13(5)： 1011-1019.
19.	李國立，劉福坤，陳忠豪，等. 胃癌術前選擇性動脈化療對組織和細胞結構的影響[J]. 中華外科雜志， 1997， 35(5)： 259-261.
20.	Becker K,Mueller JD,Schulmacher C,et al.Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer， 2003， 98(7)：1521-1530.
21.	Ajani JA, Mansfield PF, Janjan N, et al.Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma[J].J Clin Oncol， 2004， 22(14)：2774-2780.
22.	Ajani JA, Mansfield PF, Crane CH, et al.Paclitaxel-based chemoradiotherapy in localized gastric carcinoma：degree of pathologic response and not clinical parameters dictated patient outcome[J]. J Clin Oncol， 2005， 23(6)：1237-1244.
23.	Ajani JA, Winter K, Okawara GS,et al.PhaseⅡ trial of preop-erative chemoradiation in patients with localized gastric adenocar-cinoma (RTOG 9904)：quality of combined modality therapy and pathologic response[J]. J Clin Oncol， 2006， 24(24)：3953-3958.
24.	Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL,et al. Patterns of response after preoperative treatment in gastric cancer[J].Int J Radiat Oncol Biol Phys， 2011， 80(3)：698-704.
25.	Becker K, Langer R, Reim D,et al.Significance of histopathol-ogical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas： a summary of 480 cases[J]. Ann Surg， 2011， 253(5)：934-939.
26.	Scheer RV, Fakiris AJ, Johnstone PA.Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys， 2011， 80(4)：996-1001.
27.	Moureau-Zabotto L, Farnault B, de Chaisemartin C,et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys， 2011， 80(2)：483-491.
28.	Eich HT, Stepien A, Zimmermann C,et al.Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer ： prognostic significance of tumor regression [J]. Strahlenther Onkol， 2011， 187(4)：225-230.
29.	Gaca JG,Petersen RP,Peterson BL,et al.Pathologic nodal sta-tus predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma[J].Ann Surg Oncol， 2006， 13(3)：340-346.

1. Cunningham D,Allum,WH，Stenning,SP，et al.Perioperat-ive chemotherapy versus surgery alone for resectable gastroesoph-ageal cancer[J].N Engl J Med,2006,355(1)： 11-20.
2. Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States, National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3)：205-216.
3. World Health Organization.WHO handbook for reporting results of cancer treatment[M].Geneva, Switzerland：World Health Organization Offset Publication,1979：1-48.
4. Therasse P,Eisenhauer EA,Verweij J.RECIST revisited：a review of validation studies on tumour assessment[J].Eur J Cancer，2006，42(8)：1031-1039.
5. Lee SM,Kim SH,Lee JM,et al.Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoad-juvant chemotherapy in advanced gastric cancer[J].Abdom Imaging,2009,34(4)：430-440.
6. Benjamin RS,Choi H,Macapinlac HA,et al.We should desist using recist,at least in GIST[J].J Clin Oncol,2007,25(13)：1760-1764.
7. Ratain MJ,Eckhardt SG.PhaseⅡ studies of modern drugs directed against new targets：if you are fazed, too, then resist recist[J].J Clin Oncol， 2004， 22(22)：4442-4445.
8. Choi H,Charnsangavej C,de Castro Faria S,et al.CT evaluationof the response of gastrointestinal stromal tumors after imatinib mesylate treatment： a quantitative analysis correlated with FDG PET findings[J].AJR Am J Roentgenol， 2004， 183(6)：1619-1628.
9. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy：importance of size and attenuation on contrast-enhancedct[J].AJR Am J Roentgenol， 2010， 194(1)：157-165.
10. Chun YS,Vauthey JN, Boonsirikamchai P,et al.Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases[J].Jama， 2009， 302(21)：2338-2344.
11. Stacchiotti S, Collini P, Messina A,et al.High-grade soft-tissue sarcomas：tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria[J]. Radiology， 2009， 251(2)：447-456.
12. Miles KA. Tumour angiogenesis and its relation to contrast enha-ncement on computed tomography：a review[J]. Eur J Radiol，1999， 30(3)： 198-205.
13. Miles KA, Charnsangavej C,Lee FT,et al.Application of CT in the investigation of angiogenesis in oncology[J].Acad Radiol， 2000， 7(10)：840-850.
14. Beer AJ,Wieder HA,Lordick F,et al.Adenocarcinomas of es-ophagogastric junction： multi-detector row CT to evaluate early response to neoadjuvant chemotherapy[J].Radiology，2006，239(2)：472-480.
15. Maitland ML. Volumes to learn：advancing therapeutics with innovative computed tomography image data analysis[J].Clin Cancer Res， 2010， 16(18)：4493-4495.
16. Ott K, Herrmann K, Schuster T,et al.Molecular imaging of proliferation and glucose utilization： utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer[J].Ann Surg Oncol, 2011， 18(12)： 3316-3323.
17. Rosenberg R, Herrmann K, Gertler R,et al.The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT[J].Int J Colorectal Dis， 2009， 24(2)：191-200.
18. Herrmann K, Bundschuh RA, Rosenberg R,et al.Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI[J].Mol Imaging Biol, 2011， 13(5)： 1011-1019.
19. 李國立，劉福坤，陳忠豪，等. 胃癌術前選擇性動脈化療對組織和細胞結構的影響[J]. 中華外科雜志， 1997， 35(5)： 259-261.
20. Becker K,Mueller JD,Schulmacher C,et al.Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer， 2003， 98(7)：1521-1530.
21. Ajani JA, Mansfield PF, Janjan N, et al.Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma[J].J Clin Oncol， 2004， 22(14)：2774-2780.
22. Ajani JA, Mansfield PF, Crane CH, et al.Paclitaxel-based chemoradiotherapy in localized gastric carcinoma：degree of pathologic response and not clinical parameters dictated patient outcome[J]. J Clin Oncol， 2005， 23(6)：1237-1244.
23. Ajani JA, Winter K, Okawara GS,et al.PhaseⅡ trial of preop-erative chemoradiation in patients with localized gastric adenocar-cinoma (RTOG 9904)：quality of combined modality therapy and pathologic response[J]. J Clin Oncol， 2006， 24(24)：3953-3958.
24. Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL,et al. Patterns of response after preoperative treatment in gastric cancer[J].Int J Radiat Oncol Biol Phys， 2011， 80(3)：698-704.
25. Becker K, Langer R, Reim D,et al.Significance of histopathol-ogical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas： a summary of 480 cases[J]. Ann Surg， 2011， 253(5)：934-939.
26. Scheer RV, Fakiris AJ, Johnstone PA.Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys， 2011， 80(4)：996-1001.
27. Moureau-Zabotto L, Farnault B, de Chaisemartin C,et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys， 2011， 80(2)：483-491.
28. Eich HT, Stepien A, Zimmermann C,et al.Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer ： prognostic significance of tumor regression [J]. Strahlenther Onkol， 2011， 187(4)：225-230.
29. Gaca JG,Petersen RP,Peterson BL,et al.Pathologic nodal sta-tus predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma[J].Ann Surg Oncol， 2006， 13(3)：340-346.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Response Evaluation Criteria for Gastric Cancer Patients Following Preoperative Chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Format

Content